We scan new podcasts and send you the top 5 insights daily.
Bostwick says Breyer's family-office structure is an evergreen fund with no fixed fund cycle, which lets it stay with companies through long development periods. He notes great science is not always fast and sometimes takes a decade, so patient capital becomes a real strategic advantage.
Beyond the thesis, first-time biotech funds must explicitly align with LPs on the 6-to-9-year journey from seed to exit. Daniel Fero stresses finding LPs who understand their capital will be locked up for a long duration, unlike in crossover funds with shorter horizons. This "psychological fit" on capital flow expectations is crucial for a stable fund.
Tracy Britt Cool says Cambric uses a 15-plus-year structure so investors and business owners self-select for long horizons. The fund can return capital through recaps—JM Test returned its initial investment while Cambric still owned more than 70% of the business—without forcing a premature sale early.
The biggest venture outcomes often take 8-10 years or more to mature. Instead of optimizing for quick IRR, early-stage VCs should embrace long holding periods. This "duration" is a feature that allows for massive value creation and aligns with building truly transformative companies, prioritizing multiples over short-term gains.
Unlike traditional private equity firms with a 3-5 year exit timeline, Long Lake is structured as a permanent capital operating company. This allows them to make the necessary long-term, upfront investments in AI and technology to fundamentally transform the businesses they acquire.
Unlike serial venture capital financing tied to milestones, Blackstone's model commits the total capital required for a drug's entire development through approval. This removes financing risk from market volatility, which is particularly advantageous for capital-intensive, long-timeline fields like neuroscience.
Drug development can take a decade, a timeframe that misaligns with typical investor horizons and employee careers. Success requires navigating fluctuating capital market cycles and implementing strategies to retain key scientific talent for the long haul.
Sustaining an employee-owned model for over a decade frees life sciences ventures from traditional venture capital growth pressures. This self-funded corporate structure allows leadership to retain strategic autonomy and make decisions based on what best serves the patient.
When raising for a "civilization tech" company, Colossal purposefully avoided investors seeking 4-5 year fund returns. They targeted patient capital from system-builders like Jim Breyer and Thomas Tull, who have experience backing foundational technologies like the internet and quantum computing and understand multi-decade horizons for creating new economies.
Bostwick says Breyer starts with biological ground truth, demands a clean unmet-need statement, and asks explicitly why a given modality is the right tool. The firm avoids incremental improvements and backs high-risk, programmable, paradigm-shifting platforms where medicine is treated more like an information science.
A massive, multi-trillion dollar wealth transfer is making family offices more institutionalized and eager to diversify into alternative investments like life sciences. Luba Greenwood points to this as a significant, often overlooked fundraising channel for biotech companies seeking direct investment.